MA51288B1 - Analogues d'incrétine et leurs utilisations - Google Patents

Analogues d'incrétine et leurs utilisations

Info

Publication number
MA51288B1
MA51288B1 MA51288A MA51288A MA51288B1 MA 51288 B1 MA51288 B1 MA 51288B1 MA 51288 A MA51288 A MA 51288A MA 51288 A MA51288 A MA 51288A MA 51288 B1 MA51288 B1 MA 51288B1
Authority
MA
Morocco
Prior art keywords
incretin analogs
activity
receptors
incretin
analogs
Prior art date
Application number
MA51288A
Other languages
English (en)
Other versions
MA51288A (fr
Inventor
Jorge Alsina-Fernandez
Lili Guo
Tamer Coskun
Hongchang Qu
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of MA51288A publication Critical patent/MA51288A/fr
Publication of MA51288B1 publication Critical patent/MA51288B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Details Of Garments (AREA)

Abstract

L'invention concerne des analogues d'incrétine qui ont une activité au niveau de chacun des récepteurs de GIP, GLP-1 et glucagon. Les analogues d'incrétine ont des caractéristiques structurales conduisant à une activité équilibrée et une durée d'action prolongée à chacun de ces récepteurs. L'invention concerne également des procédés de traitement de maladies telles que le diabète sucré, la dyslipidémie, la stéatose hépatique, le syndrome métabolique, la stéatohépatite non alcoolique et l'obésité.
MA51288A 2017-12-21 2018-12-14 Analogues d'incrétine et leurs utilisations MA51288B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762608613P 2017-12-21 2017-12-21
PCT/US2018/065663 WO2019125938A1 (fr) 2017-12-21 2018-12-14 Analogues d'incrétine et leurs utilisations
EP18830618.7A EP3727426B1 (fr) 2017-12-21 2018-12-14 Analogues d'incrétine et leurs utilisations

Publications (2)

Publication Number Publication Date
MA51288A MA51288A (fr) 2021-03-31
MA51288B1 true MA51288B1 (fr) 2026-02-27

Family

ID=65003519

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51288A MA51288B1 (fr) 2017-12-21 2018-12-14 Analogues d'incrétine et leurs utilisations

Country Status (36)

Country Link
US (4) US11542313B2 (fr)
EP (2) EP3727426B1 (fr)
JP (3) JP6961838B2 (fr)
KR (2) KR102444783B1 (fr)
CN (1) CN111491658B (fr)
AR (1) AR113486A1 (fr)
AU (1) AU2018388962B2 (fr)
BR (1) BR112020010244A2 (fr)
CA (1) CA3084005C (fr)
CL (1) CL2020001635A1 (fr)
CO (1) CO2020006255A2 (fr)
CR (1) CR20200255A (fr)
DK (1) DK3727426T3 (fr)
DO (1) DOP2020000123A (fr)
EA (1) EA202091290A1 (fr)
EC (1) ECSP20032650A (fr)
ES (1) ES3061179T3 (fr)
FI (1) FI3727426T3 (fr)
HR (1) HRP20260186T1 (fr)
IL (2) IL325353A (fr)
JO (1) JOP20200137B1 (fr)
LT (1) LT3727426T (fr)
MA (1) MA51288B1 (fr)
MD (1) MD3727426T2 (fr)
MX (2) MX2020006548A (fr)
MY (1) MY199143A (fr)
PE (2) PE20210162A1 (fr)
PH (1) PH12020551025A1 (fr)
PL (1) PL3727426T3 (fr)
PT (1) PT3727426T (fr)
RS (1) RS67748B1 (fr)
SG (1) SG11202005606VA (fr)
SI (1) SI3727426T1 (fr)
TW (3) TWI912614B (fr)
UA (1) UA129012C2 (fr)
WO (1) WO2019125938A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
EP3882263A4 (fr) * 2018-11-12 2022-08-31 Tianjin Institute Of Pharmaceutical Research Co., Ltd. Peptide dérivé du glucagon et utilisation associée
KR102812908B1 (ko) * 2019-08-19 2025-05-28 일라이 릴리 앤드 캄파니 인크레틴 유사체의 제조 방법
US20250346647A2 (en) * 2019-12-03 2025-11-13 Antag Therapeutics Aps Optimized GIP Peptide Analogues
AR120714A1 (es) * 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
CN115335395A (zh) * 2020-03-25 2022-11-11 武田药品工业株式会社 Gip受体激动剂肽化合物的qd给药及其用途
US20230391845A1 (en) 2020-10-30 2023-12-07 Novo Nordisk A/S Glp-1, gip and glucagon receptor triple agonists
CN114685642B (zh) * 2020-12-29 2024-03-29 浙江和泽医药科技股份有限公司 一种肠促胰岛素类似物药学上可接受盐及制备方法和用途
CA3204051A1 (fr) 2021-01-20 2022-07-28 Brian Lian Compositions et procedes pour le traitement de troubles metaboliques et hepatiques
TWI837615B (zh) * 2021-03-23 2024-04-01 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途
WO2022247701A1 (fr) 2021-05-26 2022-12-01 联邦生物科技(珠海横琴)有限公司 Multi-agoniste et son utilisation
WO2022268029A1 (fr) * 2021-06-21 2022-12-29 广东东阳光药业有限公司 Agoniste triple pour récepteurs glp-1, gcg et gip
CA3223313A1 (fr) 2021-06-23 2022-12-29 Eli Lilly And Company Methodes d'utilisation et compositions comprenant un analogue d'incretine
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
TWI828434B (zh) * 2021-11-19 2024-01-01 大陸商南京明德新藥研發有限公司 釘合肽及其應用
AU2022392980B2 (en) * 2021-11-19 2025-12-18 Jiangsu Deyuan Pharmaceutical Co., Ltd. Stapled peptide and use thereof
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN114957387B (zh) * 2022-05-18 2023-06-20 华南理工大学 一种具有降血糖作用的巴旦木多肽及其制备方法与应用
JP2025530743A (ja) 2022-08-29 2025-09-17 イーライ リリー アンド カンパニー 経口投与のための組成物
AU2023348864A1 (en) * 2022-09-28 2025-03-20 Sunshine Lake Pharma Co., Ltd. Glp-1/gcg/gip triple-receptor agonist and use thereof
IL320036A (en) * 2022-10-05 2025-06-01 Lilly Co Eli Peptides for incretin synthesis
KR20250110330A (ko) * 2022-11-21 2025-07-18 일라이 릴리 앤드 캄파니 Gip/glp1 이중 효능제의 제조 방법
JP2026502943A (ja) 2022-12-30 2026-01-27 アルギファルマ エーエス 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
US20240270821A1 (en) 2023-01-31 2024-08-15 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof
CN118684758A (zh) * 2023-03-23 2024-09-24 上海民为生物技术有限公司 肠促胰岛素类似物及其应用
WO2024213022A1 (fr) * 2023-04-11 2024-10-17 上海多米瑞生物技术有限公司 Analogues d'incrétine et leur procédé de préparation, et utilisation
KR20260022948A (ko) * 2023-06-09 2026-02-20 썬 파마슈티컬 인더스트리스 리미티드 Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
KR20240176455A (ko) 2023-06-15 2024-12-24 노보 노르디스크 에이/에스 시클로덱스트린을 포함하는 약학적 제형
CN117024528B (zh) * 2023-07-07 2024-03-22 杭州信海医药科技有限公司 一种Retatrutide的制备方法
AU2024291989A1 (en) 2023-07-14 2026-01-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Glp-1, gip and gcg receptor triagonist and use thereof
WO2025087353A1 (fr) * 2023-10-26 2025-05-01 齐鲁制药有限公司 Polypeptide présentant une activité multi-agoniste et son utilisation
CN120349393A (zh) * 2023-11-06 2025-07-22 成都奥达生物科技有限公司 一种三激动剂化合物
WO2025162423A1 (fr) * 2024-02-02 2025-08-07 杭州先为达生物科技股份有限公司 Triagoniste pour glp-1r, gipr et gcgr
WO2025264776A1 (fr) * 2024-06-21 2025-12-26 Neurocrine Biosciences, Inc. Peptides chimiquement modifiés et leur utilisation
WO2025264809A1 (fr) * 2024-06-21 2025-12-26 Neurocrine Biosciences, Inc. Peptides chimiquement modifiés et leur utilisation
WO2025264785A1 (fr) * 2024-06-21 2025-12-26 Neurocrine Biosciences, Inc. Peptides chimiquement modifiés et leur utilisation
CN119978101B (zh) * 2024-07-30 2025-10-10 四川普康药业有限公司 多肽化合物及其应用
WO2026059846A1 (fr) 2024-09-13 2026-03-19 Eli Lilly And Company Timbre à micro-aiguilles solubles pour administration transdermique d'un peptide
WO2026073030A1 (fr) 2024-09-27 2026-04-02 Carmot Therapeutics Inc. Polythérapie à base d'analogues de peptide tyrosine-tyrosine (pyy) et d'agonistes de glp-1r
CN119823233A (zh) * 2025-03-18 2025-04-15 杭州思诺达医药科技有限责任公司 瑞他鲁肽的合成方法及瑞他鲁肽
CN120189527B (zh) * 2025-05-27 2026-04-03 广州富肽生物有限公司 一种多肽与抗体Fc片段的偶联物、药物组合物及其用途
CN120623312B (zh) * 2025-06-26 2026-01-23 乐普健糖药业(重庆)有限公司 Glp-1、gip、gcg三重受体激动剂及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105159B (zh) * 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
CN104127880A (zh) 2009-03-27 2014-11-05 葛兰素集团有限公司 药用融合体和缀合物
US20130157953A1 (en) * 2010-01-20 2013-06-20 Zealand Pharma A/S Treatment of cardiac conditions
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
WO2012153196A2 (fr) * 2011-05-10 2012-11-15 Zealand Pharma A/S Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
WO2015067715A2 (fr) 2013-11-06 2015-05-14 Zealand Pharma A/S Composés agonistes doubles de gip et glp-1 et procédés associés
CN105829339B (zh) * 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
TWI582109B (zh) * 2015-01-09 2017-05-11 美國禮來大藥廠 Ｇｉｐ及ｇｌｐ－１共促效劑化合物
WO2016198624A1 (fr) 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
TWI700291B (zh) * 2015-06-22 2020-08-01 美國禮來大藥廠 升糖素及glp-1共激動劑化合物
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
SG11201805586SA (en) 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
EP3217027A1 (fr) 2016-03-08 2017-09-13 HILTI Aktiengesellschaft Élement de revetement large destine a entourer une tige d'ancrage
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CN119499352A (zh) * 2018-07-23 2025-02-25 伊莱利利公司 使用gip/glp1共激动剂用于糖尿病的方法
KR20240051304A (ko) * 2018-07-23 2024-04-19 일라이 릴리 앤드 캄파니 Gip/glp1 공효능제 화합물
AR119471A1 (es) * 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
AR120714A1 (es) * 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
IL294955A (en) * 2020-01-23 2022-09-01 Lilly Co Eli Cobalt-agonist gip/glp1 compounds
US20240270821A1 (en) * 2023-01-31 2024-08-15 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof

Also Published As

Publication number Publication date
CL2020001635A1 (es) 2020-10-16
JP2022033724A (ja) 2022-03-02
EP4691555A2 (fr) 2026-02-11
ES3061179T3 (en) 2026-03-31
PT3727426T (pt) 2026-02-03
US20250313605A1 (en) 2025-10-09
MX2024010201A (es) 2024-08-26
SI3727426T1 (sl) 2026-04-30
KR20220133304A (ko) 2022-10-04
US20250059251A1 (en) 2025-02-20
CR20200255A (es) 2020-07-12
WO2019125938A1 (fr) 2019-06-27
AU2018388962A1 (en) 2020-06-04
AU2018388962B2 (en) 2020-11-19
CA3084005A1 (fr) 2019-06-27
TW202202518A (zh) 2022-01-16
CN111491658A (zh) 2020-08-04
MD3727426T2 (ro) 2026-04-30
JP6961838B2 (ja) 2021-11-05
JOP20200137A1 (ar) 2022-10-30
MX2020006548A (es) 2020-09-14
CN111491658B (zh) 2024-04-26
EP3727426B1 (fr) 2025-11-26
HRP20260186T1 (hr) 2026-03-27
EP3727426A1 (fr) 2020-10-28
TW202415675A (zh) 2024-04-16
TWI744579B (zh) 2021-11-01
ECSP20032650A (es) 2020-07-31
SG11202005606VA (en) 2020-07-29
EP4691555A3 (fr) 2026-04-22
JOP20200137B1 (ar) 2024-04-18
PE20251598A1 (es) 2025-06-16
US12365716B2 (en) 2025-07-22
IL275468B1 (en) 2026-01-01
JP2021506955A (ja) 2021-02-22
TW201938188A (zh) 2019-10-01
JP7658877B2 (ja) 2025-04-08
PE20210162A1 (es) 2021-01-26
EA202091290A1 (ru) 2020-09-10
US20200331980A1 (en) 2020-10-22
IL275468A (en) 2020-08-31
NZ765277A (en) 2024-08-30
KR20200088419A (ko) 2020-07-22
KR102444783B1 (ko) 2022-09-19
AR113486A1 (es) 2020-05-06
US12371465B2 (en) 2025-07-29
CA3084005C (fr) 2024-01-02
BR112020010244A2 (pt) 2020-10-13
PH12020551025A1 (en) 2021-09-06
KR102622642B1 (ko) 2024-01-10
US20230203121A1 (en) 2023-06-29
TWI809515B (zh) 2023-07-21
IL325353A (en) 2026-02-01
TWI912614B (zh) 2026-01-21
MA51288A (fr) 2021-03-31
DK3727426T3 (da) 2026-02-02
MY199143A (en) 2023-10-17
FI3727426T3 (fi) 2026-02-04
LT3727426T (lt) 2026-02-10
US11542313B2 (en) 2023-01-03
CO2020006255A2 (es) 2020-05-29
JP2025093970A (ja) 2025-06-24
UA129012C2 (uk) 2024-12-25
PL3727426T3 (pl) 2026-03-16
RS67748B1 (sr) 2026-03-31
DOP2020000123A (es) 2020-08-31

Similar Documents

Publication Publication Date Title
MX2024010201A (es) Analogos de incretina y sus usos.
MX2025003745A (es) Analogos de incretina y sus usos
CR20220279A (es) Análogos de incretina y sus usos
MX382408B (es) Coagonistas de los receptores de glucagón y de glp-1.
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
MX368435B (es) Analogos del glucagon.
MY176022A (en) Acylated glucagon analogues
MX380322B (es) Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1).
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
JOP20200231B1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MX2017012864A (es) Analogo acilado del glucagon.